The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.
The data appeared to slam the door on the idea that the advent of GLP-1 drugs would eliminate demand for drugs specifically ...
Investing on MSN6d
Eli Lilly stock dips on Novo Nordisk's rival drug dataNovo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...
Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...
Zacks.com on MSN1d
How to Play NVO Stock After New Drug's Success in Obesity StudyNovo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
INSIDER on MSN6d
A woman regained weight after she stopped taking semaglutide. Now she works 2 jobs to afford it.A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...
The shortage, which began in December 2022 for Mounjaro and extended to Zepbound in April 2023 ... “For Lilly, this is surely progress, but for many patients, at least in the near term, I ...
The progress that DeepSeek is making raises questions ... Wegovy and Eli Lilly's (LLY) Zepbound, had even better outcomes, indicating that those drugs were not the source of the improvement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback